Melissa Eng

408 total citations
13 papers, 303 citations indexed

About

Melissa Eng is a scholar working on Oncology, Reproductive Medicine and Molecular Biology. According to data from OpenAlex, Melissa Eng has authored 13 papers receiving a total of 303 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 5 papers in Reproductive Medicine and 3 papers in Molecular Biology. Recurrent topics in Melissa Eng's work include Ovarian cancer diagnosis and treatment (5 papers), Endometrial and Cervical Cancer Treatments (3 papers) and Cancer therapeutics and mechanisms (2 papers). Melissa Eng is often cited by papers focused on Ovarian cancer diagnosis and treatment (5 papers), Endometrial and Cervical Cancer Treatments (3 papers) and Cancer therapeutics and mechanisms (2 papers). Melissa Eng collaborates with scholars based in United States and Germany. Melissa Eng's co-authors include Amin S. Ghabrial, Yanjun Song, Leonard B. Saltz, David P. Kelsen, David R. Spriggs, Nancy E. Kemeny, Larry J. Schaaf, Paula K. Locker, Allan B. Dietz and Brian A. Staton and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Clinical Cancer Research.

In The Last Decade

Melissa Eng

13 papers receiving 295 citations

Peers

Countries citing papers authored by Melissa Eng

Since Specialization

Citations

This map shows the geographic impact of Melissa Eng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Melissa Eng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Melissa Eng more than expected).

Fields of papers citing papers by Melissa Eng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Melissa Eng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Melissa Eng. The network helps show where Melissa Eng may publish in the future.

Co-authorship network of co-authors of Melissa Eng

This figure shows the co-authorship network connecting the top 25 collaborators of Melissa Eng. A scholar is included among the top collaborators of Melissa Eng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Melissa Eng. Melissa Eng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work	Indexed citations
1	The Anti-Cancer Role of Pterostilbene in Endometrial Cancer: A Phase II Prospective, Randomized, Window-of-Opportunity Clinical Trial with Megestrol Acetate 2025 ·Antioxidants ·(unknown), (unknown), Xiwei Wu, Paul Frankel, Nora Ruel, Susan E. Yost, Mehdi Kebria, Ernest Han, (unknown), María León, (unknown), Melissa Eng, (unknown), Behrouz Salehian, Aimin Li, Daniel Schmolze, Sue Chang, Javier Arias‐Stella, Thanh H. Dellinger	1
2	A phase I study of Mirvetuximab Soravtansine and gemcitabine in patients with FRα-positive recurrent ovarian, primary peritoneal, fallopian tube, or endometrial cancer, or triple negative breast cancer 2024 ·Gynecologic Oncology ·Mihaela Cristea, Daphne Stewart, Timothy W. Synold, Nora Ruel, Joanne Mortimer, Wenge Wang, Alexander Jung, Sharon P. Wilczynski, Gottfried E. Konecny, Melissa Eng, (unknown), Ernest Han, Thanh H. Dellinger, Amy Hakim, Stephen Lee, Robert J. Morgan, Mark T. Wakabayashi, Paul Frankel	9
3	Differential gene expression analysis of a phase II randomized clinical trial of patients with endometrial cancer (EC) treated with megestrol acetate ± pterostilbene. 2024 ·Journal of Clinical Oncology ·Thanh H. Dellinger, Xiwei Wu, (unknown), Susan E. Yost, Nora Ruel, (unknown), (unknown), Paul Frankel, Mehdi Kebria, Ernest Han, (unknown), (unknown), Melissa Eng, (unknown), Daniel Schmolze, Sue Chang, (unknown)	1
4	Immunologic Signatures of Peripheral Blood T Cells Reveal the Outcome of p53MVA Vaccine and Pembrolizumab Treatment in Patients with Advanced Ovarian Cancer 2023 ·Cancer Research Communications ·Ferdynand J. Kos, Paul Frankel, Mihaela Cristea, Melissa Eng, (unknown), (unknown), Nora Ruel, Daphne Stewart, Thanh H. Dellinger, Don J. Diamond	2
5	Safety and efficacy of PIPAC in patients with ovarian cancer with peritoneal metastases: A first-in-US phase I study. 2023 ·Journal of Clinical Oncology ·(unknown), Daphne Stewart, (unknown), Nora Ruel, Paul Frankel, Yanghee Woo, I. Benjamin Paz, Yuman Fong, (unknown), Melissa Eng, (unknown), Joanne Mortimer, Richard L. Whelan, (unknown), Amit Merchea, Mihaela Cristea, Mustafa Raoof, Sarah Cole, Thanh H. Dellinger	2
6	Multicenter dose-escalation Phase I trial of mitomycin C pressurized intraperitoneal aerosolized chemotherapy in combination with systemic chemotherapy for appendiceal and colorectal peritoneal metastases: rationale and design 2022 ·SHILAP Revista de lepidopterología ·Mustafa Raoof, Kevin M. Sullivan, Paul Frankel, Marwan Fakih, Timothy W. Synold, Dean Lim, Yanghee Woo, I. Benjamin Paz, Yuman Fong, Rebecca Thomas, Sue Chang, Melissa Eng, (unknown), Richard L. Whelan, Danielle K. DePeralta, Marc A. Reymond, Jeremy Jones, Amit Merchea, Thanh H. Dellinger	6
7	A phase I study of mirvetuximab soravtansine (MIRV) and gemcitabine (G) in patients (Pts) with selected frα-positive solid tumors: Results in the ovarian cancer (EC) cohort. 2021 ·Journal of Clinical Oncology ·Mihaela Cristea, Nora Ruel, Paul Frankel, Timothy W. Synold, Daphne Stewart, (unknown), Alexander Jung, Sharon P. Wilczynski, (unknown), Gottfried E. Konecny, Melissa Eng, (unknown), Yi‐Jen Chen, Scott Glaser, Thanh H. Dellinger, Amy Hakim, Stephen Lee, Robert J. Morgan, Ernest Han	3
8	863P A phase I study of mirvetuximab soravtansine (MIRV) and gemcitabine (G) in pts with selected FRα -positive solid tumours: Results in the endometrial cancer (EC) cohort 2020 ·Annals of Oncology ·Mihaela Cristea, Paul Frankel, Timothy W. Synold, David B. Stewart, (unknown), Alain C. Jung, Sharon P. Wilczynski, (unknown), Gottfried E. Konecny, Melissa Eng, (unknown), Yi–Ju Chen, (unknown), (unknown), Thanh H. Dellinger, Amy Hakim, (unknown), Richard J. Morgan, (unknown), Mark T. Wakabayashi	1
9	A phase I study of mirvetuximab soravtansine (IMGN853) and gemcitabine (G) in patients with FOLR1-positive recurrent epithelial ovarian (EOC), endometrial cancer (EC), or triple-negative breast cancer (TNBC). 2019 ·Journal of Clinical Oncology ·Mihaela Cristea, Paul Frankel, Timothy W. Synold, Joanne Mortimer, Daphne Stewart, (unknown), Alexander Jung, Sharon P. Wilczynski, Gottfried E. Konecny, (unknown), Melissa Eng, (unknown), Yi‐Jen Chen, Scott Glaser, Ernest Han, Thanh H. Dellinger, Amy Hakim, Stephen Lee, Robert J. Morgan, Mark T. Wakabayashi	1
10	p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy 2018 ·Clinical Cancer Research ·Nicola Hardwick, Paul Frankel, Christopher Ruel, Julie Kilpatrick, Weimin Tsai, Ferdynand Kos, Teodora Kaltcheva, Lucille Leong, Robert J. Morgan, Vincent Chung, (unknown), Melissa Eng, Sharon P. Wilczynski, Joshua D.I. Ellenhorn, Don J. Diamond, Mihaela Cristea	54
11	Focal Defects in Single-Celled Tubes Mutant for Cerebral Cavernous Malformation 3, GCKIII, or NSF2 2013 ·Developmental Cell ·Yanjun Song, Melissa Eng, Amin S. Ghabrial	44
12	Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors. 1998 ·Journal of Clinical Oncology ·Leonard B. Saltz, David R. Spriggs, Larry J. Schaaf, Gary K. Schwartz, David H. Ilson, Nancy E. Kemeny, (unknown), (unknown), Melissa Eng, Patricia Albanese, (unknown), (unknown), Gary Elfring, L.L. Miller, David P. Kelsen	48
13	Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. 1996 ·Journal of Clinical Oncology ·Leonard B. Saltz, (unknown), Nancy E. Kemeny, Larry J. Schaaf, David R. Spriggs, Brian A. Staton, (unknown), (unknown), Melissa Eng, Allan B. Dietz, Paula K. Locker, David P. Kelsen	131

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact